Actively Recruiting
Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma
Led by Sun Yat-sen University · Updated on 2023-11-07
274
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study intends to evaluate the efficacy and safety of microwave ablation combined lenvatinib simultaneously for recurrent HCC
CONDITIONS
Official Title
Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Primary hepatocellular carcinoma (BCLC 0-B) confirmed by pathology
- Recurrent HCC with no prior tumor-related therapy
- Tumor count of 3 or fewer
- Tumor size of 5 cm or less
- Good performance status with Karnofsky score of 90 or higher
- Age between 18 and 75 years
- Child-Pugh liver function class A or B (score for B no more than 7)
- Baseline lab tests meeting criteria: leukocytes ≥3.0×10⁹/L; platelets ≥75×10⁹/L; hemoglobin ≥100 g/L; ALT and AST ≤3 times upper limit of normal; serum creatinine ≤1.5 times upper limit; prothrombin time less than upper limit +4 seconds; INR less than 1.5; albumin ≥30 g/L; total bilirubin ≤34 mmol/L
You will not qualify if you...
- Unwillingness to participate or follow-up
- History of other cancers
- Macrovascular invasion such as portal vein or hepatic vein tumor thrombus
- Presence of extrahepatic or lymph node metastasis
- Previous systemic therapy like targeted therapy or immunotherapy
- Previous local therapy such as ablation or TACE
- Major cardiovascular events or conditions within 12 months, including myocardial infarction, severe angina, bypass surgery, heart failure, stroke, pulmonary embolism, ongoing significant arrhythmia, or prolonged QTc interval
- Serious acute or chronic physical or mental conditions or abnormal lab results that increase risk or interfere with study participation as judged by investigators
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hunan Provincial People's Hospital
Changsha, Hunan, China, 410011
Actively Recruiting
Research Team
Q
Qunfnag Zhou, MD
CONTACT
X
Xiaohui Wang, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here